R

R

RAHME , Ramy

Last name: RAHME

First name: Ramy

2019 (v1)

Journal article

Metadata-only

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations (TP53, ASXL1, RUNX1 and EVI1) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Chiche, Edmond Bertoli, Sarah Rahme, Ramy

IntroductionCPX-351 is a liposomal formulation of cytarabine and daunorubicin packaged at a 5:1 molar ratio. This drug has recently been approved by FDA and EMEA for patients with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML).The primary objective of this study was to analyze the efficacy of...

Uploaded on: December 3, 2022
2021 (v1)

Journal article

Metadata-only

Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort

Chiche, Edmond Rahme, Ramy Bertoli, Sarah

CPX-351 is a liposomal formulation of cytarabine and daunorubicin approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). We retrospectively analyzed the efficacy and safety of CPX-351 in a real-world setting in 103 patients from 12 French...

Uploaded on: December 3, 2022